News

In a conference interview, Cohen delved into the major takeaways covered in his presentation on the latest information related to psoriasis and its therapy.

The approval was based on positive results from the phase I pharmacokinetics bridging study, which showed comparable PK and similar safety and immunogenicity of adalimumab 50 mg/mL and adalimumab high-concentration formulation.

Erin Michos, MD, MHS, discusses her choices for top studies in lipidology from the American College of Cardiology 2023 Scientific Sessions.

Prism for PTSD uses self-neuromodulation techniques to lower the amygdala-derived-EPP biomarker, which is linked to the amygdala and emotion regulation system.

In recently-presented data, ivarmacitinib was found to have decreased severity of moderate-to-severe eczema compared to placebo.

As the pandemic passes its third year, one dermatologist foresees their field's own pursuit of specialty-specific vaccination guidelines.

In the infliximab reference group, the persistence at month 12 was 94% for Crohn’s disease and 92.8% for ulcerative colitis.

An announcement from Selecta Biosciences and Sobi provide the latest update on DISSOLVE clinical program, with new data indicating SEL-212 met the primary endpoint of achieving serum urate control during month 6.

Bruce Feinberg, DO, noted that although patients and providers ultimately understand that a biosimilar should theoretically be just as effective as a biologic, prescribers may still be wary of switching patients to a different product when they have historically experienced an excellent response to the original treatment.

New phase 2 trial results suggest semaglutide 2·4 mg once weekly did not improve fibrosis without worsening of NASH in patients with NASH-related compensated cirrhosis.

New late-breaking data showed that oral roflumilast treatment was both safe and efficacious against psoriasis, making it a potentially less expensive and convenient treatment alternative.

New data demonstrates that onasemnogene abeparvovec is an effective treatment option for symptomatic and presymptomatic patients with spinal muscular atrophy (SMA).

Bruce Feinberg, DO, explained how Cardinal Health used its 2023 Biosimilars Report to better understand the provider's insight on industry changes that are occurring due to the expansion of biosimilars.

Most respondents in the multsite survey study preferred to immediately receive newly released test results via an online patient portal, despite receiving results prior to discussion with a health care provider.

New late-breaking data supported prior results indicating that all primary and secondary endpoints were reached for the IL-4Rα antibody known as CBP-201 for atopic dermatitis patients.

“We have now seen consistently across the program the potential to quite meaningfully reduce Phe levels in patients with PKU," lead investigator Dr. Jerry Vockley says in a statement.

New phase 2b data show the oral PDE4 inhibitor could reduce psoriasis area severity by more than 60% in 16 weeks.

New late-breaking data showed positive results for bimekizumab treatment of hidradenitis suppurativa, with higher response rates and a strong safety profile.

In a recent phase 2 trial, abatacept failed to significantly reduce progression to diabetes or abnormal glucose tolerance among a cohort of stage 1 relatives of people with type 1 diabetes considered to be at risk of progression.

The mean change from baseline to the day of the first masked gluten challenge in total gastrointestinal scores for the non-homozygous Nexvax2 group was 2.86 compared to 2.63 for the non-homozygous placebo group.

In research drawn from his conference presentation, Lim discussed the unique photoprotection needs of skin of color as well as some of the challenges faced by patients in this population.

An analysis of more than 500,000 pregnancies over a 15-year period suggests much of the increase in gestational diabetes rates observed during the study period can be attributed to changes in screening practices.

A small molecule IL-17A inhibitor, izokibep has additionally shown efficacy in treating psoriatic arthritis—and will now be reviewed in a phase 3 HS trial.

Pediatric dermatologist Mercedes Gonzalez, MD, discusses the new phase 3 B-SIMPLE data supporting berdazimer gel as the first potential molluscum treatment.

Kwatra spoke about his team’s research into nemolizumab for prurigo nodularis in the OLYMPIA 2 trial, including the data and its implications for the future.

New data indicates that an oral TYK2 inhibitor known as NDI-034858 showed strong results for psoriasis patients in a recent phase 2b trial.

New data has indicated that patients with psoriasis who were not responding to ixekizumab or secukinumab responded well to risankizumab, an interleukin-23 inhibitor.

Late-breaking data on roflumilast cream for eczema patients in two phase 3 trials titled INTEGUMENT-1 and INTEGUMENT-2 showed strong results for the drug.

In a new interview, Eichenfield discussed the background of his presentation on late-breaking data from the INTEGUMENT-1 and INTEGUMENT-2 trials on roflumilast for atopic dermatitis.

New phase 3 data from the BRAVE-AA trial program showed some patients who had little response to initial baricitinib achieved hair growth in year 2 of treatment.